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Keeping in mind the caveats associated with cross trial comparisons, the analysis
suggested increased effectiveness of LEN over BORT in MM patients with refracto-
ry/relapsed disease. These findings, along with its oral route of administration and
established safety profile suggest that LEN should be the preferred agent for refrac-
tory/relapsed MM.
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COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO
STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
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OBJECTIVES: Health care decision makers require estimates of the incremental
health benefit of any new technology relative to existing treatments. For treat-
ments targeting small patient subgroups, randomised controlled trial (RCT) data is
often unavailable requiring alternative methods to estimate comparative efficacy.
We illustrate two approaches, using the example of brentuximab vedotin.
METHODS: Brentuximab vedotin has been studied in HL patients relapsed follow-
ing ASCT (SG035-0003; Younes et al, JCO 2012). We compare 2-year survival data
from the 0003 study to: (1) A systematic review in ASCT failures – carried out
according to standard methods; no restrictions on study design/treatment. Per-
centages of patients alive at six-monthly intervals for up to five years were ex-
tracted. Comparative graphs were produced, with proportions of patients alive in
each study versus time; each point sized to reflect number of patients/study (2) A
large observational study, adjusted to reflect prognosis in 0003 – Martinez 2010,
reported OS according to whether patients had 0, 1 or 2 risk factors. Results were
reported for chemotherapy/radiotherapy and allogeneic SCT. Survival curves
for these comparators were re-weighted to reflect the proportion of patients with 0,
1 or 2 risk factors in the 0003 trial. RESULTS: Thirty-one studies reported retriev-
able OS for radiotherapy, chemotherapy, palliative care, or allogeneic SCT or ASCT.
OS for brentuximab vedotin was higher than or very similar to all but five small
(n13–38) studies. The adjusted Martinez 2010 comparison estimated 2 year OS of
48% and 65% for chemotherapy/radiotherapy and ASCT. OS for brentuximab
vedotin at 2 years is 65% comparing favourably to Martinez 2010. CONCLUSIONS:
Both methods suggested a favourable OS profile for brentuximab vedotin when
compared to other reported data sets. If available, access to individual patient data
from the Martinez 2010 study would allow use of more advanced methods to adjust
for potential confounders.
SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
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ECONOMIC EFFICIENCY OF FERRIC CARBOXYMALTOSE TO TREAT OR PREVENT
IRON DEFICIENCY ANEMIA: VALUE TO THE PORTUGUESE HOSPITALS
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OBJECTIVES: Among the approved intravenous iron formulations, ferric carboxy-
maltose (Ferinject®) is the most efficacious in the treatment or prevention of iron
deficiency anemia, it’s less burdensome to administer (easier and shorter time
administration) and it reduces the need for expensive resource utilization like
erythropoietin and blood transfusions. The objective was to develop a tool to assess
the relative cost-efficiency of different intravenous iron formulations in the per-
spective of the Portuguese hospitals. METHODS: A fully parameterizable Mi-
crosoft® Excel based tool was developed to compare the economic efficiency of
intravenous iron formulations available to the Portuguese hospitals: ferric car-
boxymaltose (Ferinject®); ferric hydroxide saccharose (generic and Venofer®); fer-
ric hydroxide dextran (Cosmofer®). Economic efficiency was calculate as the bal-
ance between hospitals incurred costs relative to the number of patients to be
treated, the dose and number of administrations of intravenous iron, and the need
for erythropoietin and blood transfusions. The tool default values are from a liter-
ature review used to populate the model. The tool allows studying the cost and
benefits of treating/preventing chronic kidney disease, inflammatory bowel dis-
ease, chemotherapy, and orthopedic surgery related anemia. RESULTS: Ferric hy-
droxide saccharose (generic) is to the most used and lower price intravenous iron in
Portugal. Relative to generic ferric hydroxide saccharose (FHS), ferric carboxymalt-
ose (FC) is estimated to lower mean per patient annual costs in all four anemic
conditions in major hospitals: 3,087.60€ (FC) vs. 3,482.20€ (FHS) for chronic kidney
disease; 2,195.75€ (FC) vs. 2,427.4€ (FHS) for inflammatory bowel disease; 3,626.17€
(FC) vs. 3,793.13€ (FHS) for chemotherapy; and 3,485.74€ (FC) vs. 3,849.47€ (FHS) for
orthopedic surgery. These results were consistent irrespective of the type of
hospital. CONCLUSIONS: This is a valuable tool to inform hospital decison makers
about the economic value of ferric carboxymaltose as compared to other intrave-
nous iron formulations.
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SOCIETAL BURDEN ASSOCIATED WITH NEUROPATHIC PAIN IN EUROPE
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OBJECTIVES: Neuropathic Pain (NeP) is a common disorder that can be chronic,
severe and disabling, While the burden regarding quality of life and health care
costs is understood, societal costs are less researched. This analysis addresses the
implications in terms of work productivity loss and caregiver needs. METHODS:
Data were drawn from the 2012 Adelphi NeP Disease Specific Programme, a, cross-
sectional survey of 121 primary care physicians and 292 specialists and their pa-
tients run in five European countries (France, Germany, Italy, Spain and the UK).
Physicians provided data relating to diagnosis, treatment patterns and caregiver
requirements, patients were invited to fill a self-completion questionnaire includ-
ing the Work Productivity and Activity Impairment (WPAI) questionnaire.
RESULTS:A total of 3956 patients were included, of whom 2639 were of working age
and 1341 in either full or part time employment. 23% of those employed were
currently on sick leave, with mean duration of absence being 10 weeks. A total of
751 patients completed the WPAI; of whom 30% reported that NeP had stopped
them from working (limited periods or permanently). These patients reported ab-
senteeism from work 23% of the time. Whilst at work, on a scale of 0 (no effect) to
10 (complete prevention from work) patients reported a mean score of 4.4, implying
significantly reduced on-the-job effectiveness. Regarding regular daily activities
(housework, shopping etc.) on a similar scale from 0 to 10 patients again reported a
value of 4.4; 19% of patients had a caregiver responsible for their daily activities.
The most common caregiver was partner/spouse (66%) while only 15% received
care from a professional caregiver. The mean amount of care provided was 27
hours per week across Europe, ranging from 10 hours (France) to 48 hours (Italy).
CONCLUSIONS: This abstract implies evidence suggesting a major societal burden
within humanistic and economic societal burden associated with NeP in Europe.
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OBJECTIVES: NNT can be a useful approach to compare treatments in the absence
of direct comparative clinical trials. Imatinib, nilotinib and dasatinib are approved
as first-line treatments for patients newly diagnosed with Philadelphia chromo-
some positive chronic myeloid leukemia in the chronic phase (CP-CML). The objec-
tive of this analysis is to compare these treatments with regards to: (1) the NNT to
achieve one MMR by 12 months (2) the cost of achieving one MMR and the annual
cost treatment including of adverse events (AEs) from the perspective of the Greek
National Health System (NHS). METHODS: MMR and AE rates were taken from the
CML-CP frontline trials –DASISION (dasatinib 100mg QD vs. imatinib 400mg QD)
and ENESTnd (nilotinib 300mg BID vs imatinib 400mg QD). The NNT was calculated
as the inverse of the MMR rate by 12 months (1/MMR). AE management costs were
estimated from patient records at Evangelismos Hospital and multiplied by the
incidence reported in the trials. RESULTS: The nilotinib NNT was 51% lower than
the imatinib NNT in ENESTnd (1.8 vs. 3.7) and the dasatinib NNT was 39% lower that
the imatinib NNT in DASISION (2.2 vs. 3.6). Annual cost of nilotinib including cost of
AEs is estimated at €34.349, dasatinib €35.504 and of imatinib €25.040. The cost of
achieving 1 MMR is €62.453 for nilotinib, €78.389 for dasatinib and €92.741 for ima-
tinib. Therefore, the cost of achieving 1 MMR with nilotinib is lower by 20,33% vs.
dasatinib and 33% vs. imatinib. CONCLUSIONS: The NNT findings and the differ-
ential cost of managing AEs in each treatment from this evaluation suggests that
nilotinib provides better clinical outcomes and would result in lower costs for
hematologic AE management from the perspective of the Greek NHS.
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NEUROPATHIC PAIN COMPONENTS IN DENMARK
Sætterstrøm B1, Poulsen PB2, Olsen J1, Strand M2, Schiøttz-Christensen B3
1University of Southern Denmark, Odense, Denmark, 2Pfizer Denmark, Ballerup, Denmark,
3Aarhus Rheumatologic Clinic, Aarhus, Denmark
OBJECTIVES:To evaluate the health care and productivity costs in chronic low back
pain (CLBP) patients with a probable neuropathic pain (NeP) component before and
after the initiation of pregabalin, gabapentin or a TCA (tricycle antidepressant).
METHODS: Patients with primary diagnosis of CLBP (ICD-10: M43, M45-48, M50-51,
M53-54) and at least two prescription claims for either pregabalin, gabapentin or a
TCA were identified using data from the National Patient Registry, the Medicinal
Registry, and other registries (2004-2010). Patients identified with generalized anx-
iety disorders or seizures were excluded. The index date was considered the first
prescription for pregabalin, gabapentin or a TCA. Descriptive assessments of
health care and productivity costs were conducted 12 months pre and 12 months
post the index date using the full dataset. To control for selection bias, a propensity
score matched cohort controlling for age, gender, socioeconomic status, education,
depression, and health care resource use was also conducted. Statistical tests per-
formed were Wilcoxon (0.05). RESULTS: A total of 6,028 of 7,282 CLBP patients
with NeP met the inclusion criteria (treatment courses included: 3,507 TCA; 2,735
gabapentin; 1,293 pregabalin). Twelve months health care costs increased signifi-
cantly in all 3 groups (€377 - €1,113) (P0.001). Matched sub-analyses covering 1,217
patients in each group showed similar significant health care cost increases; how-
ever, the pregabalin group was the only group to result in a significant reduction in
hospitalization costs (P0.03). Across all three groups number of job losses was
reduced, whereas long-term sickness increased; however, insignificantly so in the
pregabalin group. CONCLUSIONS: This study showed increasing healthc are costs
12 months after the initiation of NeP drug treatment in CBLP patients with NeP. In
matched analyses the increased health care costs in the pregabalin group were
partly offset by significant savings in hospitalization costs. Production lost in-
creased in all three groups; however, only significant in the TCA and gabapentin
groups.
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AN INDIRECT COMPARISON OF ICATIBANT AND FOUR OTHER THERAPIES FOR
THE SYMPTOMATIC TREATMENT OF ACUTE ATTACKS OF HEREDITARY
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